WASHINGTON (MedPage Today) — The FDA has approved clonidine hydrochloride (Kapvay) as the first attention deficit hyperactivity disorder (ADHD) drug concomitantly used with a stimulant.
No Comments »
Filed under: General Health News
(MedPage Today) — Special courts for mentally ill patients may lower subsequent arrest rates and jail time, researchers have found.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — Although the healthcare reform law forbids it, using cost factors in comparative effectiveness research could save billions of dollars and put Medicare on a more secure financial footing, researchers argued.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — The FDA has approved clonidine hydrochloride (Kapvay) as the first attention deficit hyperactivity disorder (ADHD) drug concomitantly used with a stimulant.
No Comments »
Filed under: Pharmacy News
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly [...]
No Comments »
Filed under: Pharmacy News
ISTO Technologies, Inc., an orthobiologics company with a cell-based platform for cartilage regeneration, announced today the completion of patient enrollment in the Phase I clinical study for NuQu™, an injectable formulation of juvenile chondrocytes designed for the treatment of discogenic back pain. The study included 15 patients enrolled at two clinical sites. All patients [...]
No Comments »
Filed under: Pharmacy News
Archimedes Pharma US Inc. today announced publication of results from a pivotal clinical study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain (BTCP).
No Comments »
Filed under: Pharmacy News
Enzon Pharmaceuticals, Inc. today announced the publication of preclinical data demonstrating that PEG-SN38 (EZN-2208), the Company’s novel PEGylated DNA topoisomerase I inhibitor, led to significantly greater tumor regression as compared to CPT-11 (irinotecan) in both in vitro and in vivo models of pediatric neuroblastoma.
No Comments »
Filed under: Pharmacy News
ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that the company’s clinical data from ICT-107 will be featured in two oral sessions at the World Stem Cell Summit, which is being held October 4-6 in Detroit, MI.
No Comments »
Filed under: Pharmacy News
Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company has achieved last patient out in two studies: a Phase 1 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou [...]
No Comments »
Filed under: Pharmacy News
